Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C.
Neelapu SS, et al. Among authors: depuy v.
Blood Adv. 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848.
Blood Adv. 2021.
PMID: 34478487
Free PMC article.